North America Vaccines Market Analysis and Forecast by Size, Share, Growth, Trends 2031

The North America Vaccines Market size is expected to reach US$ 50,877.2 Million by 2031 from US$ 34,058.6 Million in 2024. The market is estimated to record a CAGR of 5.9% from 2025 to 2031.

Executive Summary and North America Vaccines Market Analysis:

In 2024, the United States largely dominated the North American vaccines market and held the largest market share among the countries in the region, which also included Canada and Mexico. This position is likely to continue, primarily because of the increasing outbreak of infectious diseases in the country. The increasing need for quality immunization has resulted in the expansion of mass immunization programs focused on disease control and prevention of outbreaks. Such programs not only increase public health coverage but also lead to substantial investments in vaccine research and development and manufacturing facilities. The US government and healthcare agencies are actively pursuing policies and collaborations to enhance vaccine manufacturing capabilities, thus providing a more effective response to public health issues. Further, advancements in biotechnology and greater investment in research are driving innovation in vaccine formulation, expanding the market. Overall, this environment makes the US a prime driver of growth in the North American vaccine market.

North America Vaccines Market: Strategic Insights

North America Vaccines Market Segmentation Analysis:

• By Type, the North America Vaccines Market is segmented into Conjugated Vaccines, Inactivated Vaccines, Live Vaccines, Recombinant Vaccines, and Toxoid Vaccines. The Conjugated Vaccines segment held the largest share of the market in 2024.
• By Indication, the North America Vaccines Market is segmented into HPV, PCV, DTP, Hepatitis, Influenza, Dengue, and Other. The HPV segment held the largest share of the market in 2024.
• By Route of Administration, the North America Vaccines Market is segmented into Injection, Oral, and Other. The injection segment held the largest share of the market in 2024.
• By Age Group, the North America Vaccines Market is segmented into Pediatric and Adult. The pediatric segment held the largest share of the market in 2024.

North America Vaccines Market Players Density: Understanding Its Impact on Business Dynamics

The North America Vaccines Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

North America Vaccines Market Outlook

The World Health Organization (WHO) has identified over 30 priority pathogens that could lead to global public health emergencies. These include influenza A viruses, dengue virus, and monkeypox virus. Recently, there has been a global increase in the frequency of infectious disease outbreaks in humans. These outbreaks are caused by bacteria and viruses, most of which originate in animals or are transmitted by vectors. According to the Influenza Surveillance and Response System (GISRS) from sentinel surveillance locations, SARS-CoV-2 activity has increased globally. As of May 11, 2025, the test positivity rate was 11% across 73 reporting countries, regions, and territories. This rate is comparable to the peak observed in July 2024, which was 12% from 99 countries, and represents an increase from the 2% reported by 110 countries in mid-February 2025.

As of April 2024, the WHO reported over 7.6 million dengue cases, including 3.4 million confirmed cases, over 16,000 severe cases, and more than 3,000 deaths globally. The Americas witnessed a significant increase in dengue cases over the last five years. By the end of April 2024, the number of cases in this region exceeded 7 million, surpassing the previous annual high of 4.6 million cases recorded in 2023. Currently, 90 countries are experiencing active dengue transmission.
According to the Council on Foreign Relations, during 2022-2023, a global mpox outbreak resulted in 87,000 reported cases and 140 confirmed deaths across 111 countries. WHO declared the outbreak a Public Health Emergency of International Concern (PHEIC).

According to the WHO, in 2022, ~254 million people were living with hepatitis B, and 50 million with hepatitis C. Half of those affected by chronic hepatitis B and C infections were aged between 30 and 54 years, while 12% were children under 18 years old. Across all regions, only 13% of individuals with chronic hepatitis B infection had been diagnosed, and about 3% (i.e., ~7 million) had received antiviral therapy by the end of 2022. For hepatitis C, 36% had been diagnosed, and 20% (i.e., roughly 12.5 million) had received curative treatment. Hepatitis is preventable through vaccination, and various organizations are proposing strategies to prevent premature deaths from hepatitis. As per the WHO estimates, 4.5 million deaths can be prevented in low- and middle-income countries by 2030. WHO Member States are endorsing the WHO's global hepatitis strategy with an aim to reduce new hepatitis infections by 90% and deaths by 65% by 2030.

Outbreaks of contagious diseases significantly increase the public and government demand for vaccines. When diseases such as measles, dengue, or COVID-19 emerge or spread rapidly, the urgency to control the outbreak drives up the demand for vaccinations. For example, the global COVID-19 pandemic created unprecedented demand for vaccines worldwide, with both governments and individuals seeking rapid immunization to curb the spread of the virus and reduce mortality rates. As per the WHO, global immunization efforts have saved an estimated 154 million lives over the past 50 years, which translates to the equivalent of six lives saved every minute each year. The measles vaccination had the most significant impact on reducing infant mortality, accounting for 60% of the lives saved through immunization. As of April 2024, 84% of infants were protected with three doses of vaccine against diphtheria, tetanus, and pertussis (DTP), which serves as the global benchmark for immunization coverage.

Therefore, the surging prevalence of infectious diseases and rising vaccine-preventable disease outbreaks increase the demand for vaccines.

North America Vaccines Market Country Insights

By country, the North America Vaccines Market is segmented into the United States, Canada, and Mexico. The United States held the largest share in 2024.

According to the Centers for Disease Control and Prevention (CDC), According to the Centers for Disease Control and Prevention (CDC), the number of measles outbreaks increased from 16 in 2024 to 23 in 2025, with the proportion of outbreak-associated cases rising from 69% (198 of 285) to 89% (1,088 of 1,227), indicating a notable escalation in outbreak-driven transmission. This surge in measles cases has led to renewed efforts to increase vaccination rates for the disease. Public health authorities-such as CDC, US Department of Health and Human Services, and Advisory Committee on Immunization Practices-are urging healthcare providers to review patients' vaccination histories and recommend catch-up immunizations for children who missed their doses during the COVID-19 pandemic, which occurred between 2020 and 2022. This ongoing measles outbreak has also underscored the importance of strong vaccination recommendations and improved access to programs like Vaccines for Children (VFC).

As of June 2025, at least 270 million people-representing 81% of the US population-have received at least one dose of a COVID-19 vaccine, and 70% are considered fully vaccinated. The CDC has recommended updated COVID-19 vaccines for the 2024-2025 season for all adults and children as young as 6 months. Waning immunity and emerging viral strains emphasize the importance of timely vaccination. For the 2025-2026 season, the FDA recommends updating COVID-19 vaccines to target the LP.8.1 strain of the JN.1 variant. Concurrently, rising incidences of measles, COVID-19, and RSV are fueling greater demand for immunization.

North America Vaccines Market Company Profiles

Some of the key players operating in the market include Abbott Laboratories, GSK Plc, Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi SA, CSL Ltd, Serum Institute of India Pvt Ltd, BioNTech SE, and Sinovac Biotech Ltd.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

North America Vaccines Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note:

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise